When rat hepatocytes were incubated with albumin complexed to the n-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), rather than to oleic acid (OA), the secretion of newly synthesized apoprotein B100 (apoB100) or B48 (apoB48) was reduced, despite stimulation of cellular triglyceride synthesis by all three fatty acids. When pulse-chase studies of apoB synthesis and secretion were performed in the presence of OA, EPA, or DHA, there were no significant changes in the initial synthetic rates of either apoB species. However, during the chase period, the total recovery of labeled apoB100 and apoB48 from the cell and medium was less in the n-3 fatty acid groups, so that by 150 min, approximately half as much labeled apoB was recovered as in the OA group. Overall, the decreased accumulation in medium of labeled apoB in the presence of EPA and DHA could be quantitatively accounted for by increased degradation of intracellular apoB. Thus, in the primary hepatocyte, apoB degradation is not constitutive, but can be regulated by n-3 fatty acids. (J. Clin. Invest. 1993.
Introduction
The effects of the n-3 fatty acids found in fish oils on mammalian lipoprotein metabolism have been extensively studied because of their potential therapeutic benefits. There is a general consensus (reviewed in references 1 and 2) that enrichment of diets with either eicosapentaenoic acid (EPA) 1 or docosahexaenoic acid (DHA), two major fatty acids common in fish oils, results in a lowering of plasma triglyceride levels. However, there is no agreement concerning their mechanism of action. Hypotheses advanced thus far include (a) decreased synthesis 1 . Abbreviations used in this paper: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HepG2, a human hepatocellular carcinoma cell line; OA, oleic acid. ofhepatic triglycerides (3), (b) increased clearance oftriglyceride-rich lipoproteins by either enhanced lipolysis by lipoprotein lipase (4) or increased LDL receptor activity (5) , and (c) inhibition of the assembly or secretion of newly synthesized apoB-containing particles (6) (7) (8) .
In this article, we have focused primarily on the last mechanism by studying, in rat primary hepatocytes, the metabolism of newly synthesized apoB after exposure ofthe cells to EPA or DHA complexed to albumin (BSA). The results were compared to two control treatments; BSA alone and BSA complexed to oleic acid (OA), a model fatty acid precursor of triglycerides. Because rat liver can edit the mRNA for apoB and produce lipoprotein particles containing either the larger (apoB100) or smaller (apoB48) protein species (9-12), we were able to examine the separate effects of n-3 fatty acids on newly synthesized apoB100, apoB48, and total apoB.
As will be described, we have determined the effects in rat hepatocytes of incubation with different fatty acid-BSA complexes on three aspects of the cellular metabolism of apoB: (a) the steady-state level of apoB in cells and conditioned media; (b) the synthetic capacity of the cells for apoB, by measuring the apoB mRNA level and the initial synthetic rate of apoB; and (c) the degradation of apoB as assessed by pulse-chase analysis. The data clearly demonstrated that the intracellular degradation of apoB increased in the EPA and DHA groups, and that this increase can quantitatively account for the decrease in the secretion of newly synthesized apoB by hepatocytes incubated with the n-3 fatty acids.
Antisera
A monospecific rabbit anti-rat apoB polyclonal antiserum was kindly provided by Drs. Janet D. Sparks and Charles E. Sparks (University of Rochester). For some experiments, goat anti-rat apoB polyclonal antiserum was used. It was prepared in this laboratory as follows: The fraction containing the d < 1.020 lipoproteins was obtained by ultracentrifugation from pooled sera of sucrose-fed rats. The lipoproteins were delipidated, the resulting apoproteins separated by column chromatography, and apoB purified as previously described ( 13) . ApoB (0.5 mg) was mixed with Ribi adjuvant (Immunochem Research Inc., Hamilton, MT) and injected into the hindquarters (0.25 mg per side) of a goat. Immunizations and boosters were performed according to the manufacturer's protocol. The titer and specificity of the resulting antibodies were examined by Western blot analysis (14) . The goat antiserum had similar immunoreactivity and specificity as that of the rabbit. Pilot studies were performed to determine the titer of antiserum that would quantitatively precipitate radiolabeled apoB from cell lysate and conditioned medium. An initial immunoprecipitation was followed by a second immunoprecipitation ofthe material that remained in the supernatant. At a rabbit or goat antiserum titer of 1:300 in both immunoprecipitation reactions, no additional radiolabeled apoB was recovered from lysate or medium samples after the first immunoprecipitation.
For the immunoprecipitation of newly synthesized rat albumin, a monospecific polyclonal goat antiserum was purchased from United States Biochemical Corp. (Cleveland, OH) and reconstituted as directed by the manufacturer.
Metabolic labeling ofhepatic proteins
Steady-state studies. It had been previously reported that incubation of rat primary hepatocytes with [35S]methionine for at least 2 h will maximally label the intracellular apoB pool ( 15) . In the morning after hepatocyte isolation, cells were incubated 4 h in 3 ml of RPMI 1640 medium containing the following: 150 ,Ci [35S]methionine (1,100 Ci/ mmol, New England Nuclear, Boston, MA), and either BSA (0.16 mM) or fatty acid (FA)-BSA complex (0.8 mM OA, EPA, or DHA; 0.16 mM BSA). Incorporation oflabel into the two species ofapoB was determined by immunoprecipitation analysis as described below.
Pulse-chase studies. In the morning after hepatocyte isolation, cells were incubated for 2 h with FA-BSA complexes or BSA alone in 3.0 ml ofmethionine-free medium (RPMI 1640D) supplemented with 10M L-methionine, then changed to 2 ml of the same medium that was not supplemented with cold methionine. Incubation was continued for another 2 h. Without changing the medium, 200 MCi of [35S]methionine in 100 ,ul of RPMI 1640D were then added to each dish. Incubation with the label was continued for exactly 15 min, after which the medium from each dish was quickly withdrawn and the cell monolayers washed three times with RPMI 1640D medium supplemented with 10 mM L-methionine. The cells were then incubated in RPMI 1640D medium containing 10 mM L-methionine and either FA-BSA complexes or BSA alone for the various chase periods (as noted in the appropriate tables and figures). Immunoprecipitation analysis of labeled cellular and secreted apoB was performed as described below.
In some labeling studies, cycloheximide was employed to determine whether the effects of EPA and DHA required active protein synthesis. Two protocols were used. In protocol 1 
Immunoprecipitation analysis
At the conclusion of each experiment, the medium from each dish was transferred into an individual tube and centrifuged for 5 min at 1,000 rpm in a table top centrifuge (Beckman Instruments, Inc., Fullerton, CA) to remove debris. The cell monolayers were washed three times with salt-balanced Hanks' solution (or, in the case of pulse-chase studies, with RPMI 1640D medium containing 10 mM L-methionine), and then solubilized by addition of 1.0 ml of detergent buffer (buffer C: 0.01 M Na phosphate [pH 7.4], 0.125 M NaCl, 1% [vol/vol] Triton X-100, 1% [wt/vol] Na deoxycholate and 1% [wt/vol] lithium dodecyl sulfate). Protease inhibitors (2.0 mM benzamidine, 1.0 mM phenylmethylsulfonyl fluoride, 20 Mg/ml aprotinin, and 20 Mg/ml leupeptin) were freshly added to buffer C just before use. The dishes were placed at 370C for 15 min with shaking. The cell lysates were then pipetted into glass tubes and heated at 80C for 1 h and then reheated at 95°C for 5 min ( 16) . A 0.5-ml aliquot oflysate was diluted with 0.5 ml of a solution of 0.01 M Tris/HCl (pH 7.4) and 0.15 M NaCl and used in the subsequent steps. Media samples were diluted by mixing a 0.5-ml aliquot with 0.5 ml buffer C.
The diluted lysate and media samples were then treated to remove nonspecific proteins. To each tube was added 0. [vol/vol] glycerol, and 10 mM dithiothreitol and heating to 95°C for 5 min. After centrifugation to remove any insoluble material (2,800 rpm, 10 min), the supernatants were analyzed by electrophoresis in a 3.5% polyacrylamide-1 8% glycerol gel (17) . After staining and fixing, the gel was enhanced in fluor (Autofluor, National Diagnostics, Manville, NJ).
The enhanced gel was dried and exposed to XAR-5 film (Eastman Kodak Co., Rochester, NY) at -70°C.
Because the response of photographic film has both a high threshold and a low capacity, weak and strong fluorographic signals are often inaccurate reflections ofthe true amount of radioactivity incorporated into proteins and are appropriate for qualitative comparisons only. Therefore, when reliable quantitation of labeled apoB48, apoB100, and albumin was necessary, the appropriate radioactive bands were located by fluorography, cut out, and assayed by scintillation counting as described ( 18 ) .
Triglyceride synthesis
Cells were maintained for 6 h in the presence of [1,2,3-3H] glycerol (specific activity of 200 mCi/ mmol; New England Nuclear) and either BSA or FA-BSA complexes. Then, the conditioned medium was collected, the cell monolayer washed with PBS, and the total cellular lipids extracted with 4 ml of isopropanol. The extract was evaporated under N2 at 60C and the dried lipids dissolved in 400 Ml of isopropanol. An aliquot of 100 Ml of sample was then extracted with 4 ml of Dole's solvent (isopropanol/heptane/ 0.5 M sulfuric acid; 40:10:1 ), 100 M1 of glyceryl trioleate (2 mg/ml), 2.25 ml ofheptane, and 1.75 ml ofdH2O. The extracted lipids were mixed with 3 ml ofDole's lower phase solvent (lower phase ofa mixture of Dole's solvent/dH2O/heptane; 1.67:1:1 ), and the resulting upper phase dried as above. ScintiVerse BD (Fisher Scientific Co., Fair Lawn, NJ) was added (10 ml) and after vortexing, the amount of labeled glycerol incorporated into triglycerides was determined by scintillation counting.
To measure the incorporation of labeled glycerol into secreted triglycerides, conditioned medium (1 ml) was extracted with 8 ml of Dole's solvent, 200 Ml of glyceryl trioleate, 4.5 ml of heptane, and 3.5 ml of dH2O. The extracted lipids were mixed with 6 ml of Dole's lower phase solvent, and the resulting upper phase treated as above.
Thin-layer chromatography confirmed that for both the cellular and medium samples, > 95% of the extracted radioactive lipids were triglycerides.
RNA isolation and quantitation
Total RNA was isolated from hepatic cells at the conclusion of the experiments using a guanidinium thiocyanate-based procedure ( 19) as previously described (20) . RNA samples were blotted onto nylon membranes (Nytran, Schleicher & Schuell, Inc., Keene, NH), using a Bio-Rad Laboratories (Richmond, CA) manifold following the manufacturer's protocol. Hybridizations were performed using 32P-labeled DNA probes (random primer method [21 ]) for apoB (provided by Dr. A. J. Lusis, University ofCalifornia, Los Angeles), albumin (provided by Dr. T. Sargent, National Institutes ofHealth), and fl-actin (provided by Dr. D. Friedman, University of Texas). Unbound probes were washed under stringent conditions (0.1X SSC [0.01 5M NaCI, 0.0015M Na citrate], 1% SDS, 55°C), and the membranes exposed to XAR-5 film at -70°C. The intensities ofthe signals on the resulting autoradiograms were quantitated by densitometry.
Other methods
Protein was measured by the Lowry procedure (22) using BSA as the standard. Labeling of total cellular and medium protein was determined after TCA-phosphotungstic acid precipitation as previously described (23) . All results were normalized to the same specific activity of total cellular protein.
Statistical analysis
The intracellular data were transformed to log10 percentage recoveries and modeled by regression analysis using Quattro Pro software (Borland, Scotts Valley, CA). Equality of the slopes of the regression lines was analyzed by a modified t test (24) . Other data were analyzed by either Student's t test or the analysis of variance, using the InStat programs (GraphPad Software, San Diego, CA).
Results
Steady-state studies. In initial experiments we confirmed that the secretion by the rat hepatocyte of newly synthesized apoB was reduced in the presence of n-3 fatty acids (for example, see reference 6). Rat to immunoprecipitation analysis. As shown in Fig. 1 with previous reports (for example, references 15 and 16). The ratio oflabeled intracellular apoB100 to apoB48 for each treatment, as calculated from the data in Table I , was 0.31, 0.24, 0.27, and 0.23, for OA, BSA, EPA, and DHA, respectively. The amounts of TCA-phosphotungstic acid-precipitable labeled proteins (per milligram cell protein) in either cell lysates or conditioned media among the groups of cells were not significantly different (data not shown), indicating that the results cannot be explained by either differential uptake of [35S] methionine or toxicity ofthe n-3 fatty acids relative to OA or BSA. By considering both the intracellular and extracellular results, it is clear that, as compared to incubation with OA, there was an overall reduction in the level ofnewly synthesized and secreted apoB in the presence of EPA or DHA. Synthetic rate studies. To determine whether lower steadystate levels of intracellular apoB were due to decreased synthesis or increased degradation, both apoB mRNA levels and the initial synthetic rates of apoB under the different treatment conditions were measured. As summarized in Table II , relative to the BSA control cells, there were no statistically significant differences among fatty acid treatments in the expression ofthe apoB or control (f3-actin, albumin) genes.
To determine the initial synthetic rate of apoB, a pulsechase experimental design ( 15, 16) Figure 4 . FA effects on the disappearance of cellular apoB. Rat hepatocytes were treated as in Fig. 3 , except that after pulse-labeling with [35" ]methionine, media were changed to remove label, and incubations were continued for the indicated times in treatment media containing an excess of unlabeled methionine. At the end of each chase period, labeled apoB was isolated from cell lysate by immunoprecipitation. Quantitation of labeled apoB was done as in Fig. 3 . For each treatment condition, the percent of labeled apoB recovered relative to the 15-min time point was calculated, log transformed, and the data (log10% recovery over time) modeled by linear regression without lar apoB were then measured by immunoprecipitation and SDS-PAGE analysis. The amount oflabel incorporated into intracellular apoB at the end of the 15 min chase period was -90% of the maximum value, similar to published results ( 15, 16) . Secretion of radiolabeled apoB was not detected at the end of the chase period, consistent with the evidence that it takes -40 min for newly synthesized apoB to appear in conditioned medium ( 15, 16, 25) . Relative initial rates of synthesis in each treatment condition could therefore be reliably estimated from the amount of [ I'S] methionine incorporated into the apoB species because ofthe high degree oflabeling ofintracellular apoB after the brief pulse of isotope and the confinment of newly synthesized apoB within the cell at the end of the experiment.
As shown in Fig. 3 , the incorporation of [35S] methionine into intracellular apoB100 and apoB48 was similar among all treatment groups, indicating there were no significant (P > 0.1 ) effects of BSA, OA, EPA, or DHA on the initial synthetic rates of both species of apoB.
Pulse-chase studies ofapoB metabolism. To determine the effects of EPA and DHA on the degradation of apoB, the duration of the chase period was lengthened and the recovery of labeled apoB from cell lysates and conditioned media measured over time. As shown in Fig. 4 and Table III, in each treatment group the decay of intracellular apoB48, apoB100, or total apoB was a first-order kinetic process and the rate of decay was faster for apoB100 than for apoB48, consistent with previous studies using rat hepatocytes maintained in media that did not contain FA-BSA complexes ( 15, 16) . Comparisons among the treatment groups revealed that apoB48, apoB100, and total apoB disappeared from EPA-and DHAtreated cells more rapidly than from OA-treated cells (Fig. 4) .
This impression was confirmed by analysis of the slopes of the regression lines (Table III) . The difference was observable by the 45-min time point and became more apparent as the chase period lengthened. In contrast to hepatocytes treated with OA or BSA, in hepatocytes incubated with EPA and DHA, intracellular apoB decreased over time with no corresponding increase in medium apoB48, apoB 100, or total apoB (Fig. 5 ) . Thus, the total apoB in the system (the sum of intra-and extracellular apoB) by 45 min of chase was decreased in the cells treated with n-3 fatty acids. Addition of protease inhibitors to the media did not affect the results, indicating that extracellular degradation of apoB had not occurred.
An example of primary data obtained after 150 min of chase is shown in Fig. 6 . As compared to the OA and BSA groups, EPA and DHA treated cells had both reduced extracellular (Fig. 6 , left) and intracellular (Fig. 6 , right) levels of labeled apoB. These results (Fig. 4-6 ) indicate, then, that in the presence of n-3 fatty acids, relative to OA and BSA, substantially more of the newly synthesized apoB species was degraded.
To examine quantitatively the rapidity and magnitude of the effects ofEPA and DHA on the intracellular degradation of apoB in hepatocytes, we calculated the recoveries of labeled apoB after various chase periods relative to the peak level of isotope incorporation. These data are summarized in Table IV and Fig. 7 , and confirm the data displayed in Figs. 4-6: In the presence of n-3 fatty acids, there was an early increase in the degradation of apoB that was maintained during the longer chase periods. By 150 min ofchase, the amount ofdegradation in the n-3 fatty acid groups was at least twice that in the OA and BSA groups (P < 0.01 ). Although the intracellular steady-state levels of apoB in the BSA group were lower than those of the OA group (Fig. 2 . v X . -. * B 4 8 TIME (min) Figure 5 . FA effects on the appearance of apoB in medium. Rat hepatocytes were treated as in Fig. 4 103±9  100±9  101±9  80±9  77±9  79±9  73±12  74±19  73±9  BSA  94±3  91±3  91±3  81±5  78±4  79±4  77±3   77±7  77±5  EPA  78±3  85±4  83±4  50±5  54±5  53±5  29±4  40±1  35±4  DHA  64±9  73±10  71±10  49±4  54±8  53±6  25±4  32±4  30±1 Rat hepatocytes were treated as described in Fig. 3 . Initial quantitation of the recovery of labeled total apoB (apoBT) was done by scintillation counting of bands from gels used to separate apoB species immunoprecipitated from cell lysates and media. 4 and 5; see also Discussion).
The data plotted in Fig. 5 were also examined for differential effects ofthe n-3 fatty acids on the two species ofapoB. The average ratio of labeled apoB100 to apoB48 in the media of EPA-and DHA-treated cells after 150 min of chase (0.24) was significantly lower (P < 0.001 ) than the corresponding value for the OA and BSA groups (0.36). Thus, ofthe two species of apoB, the secretion of labeled apoB100 was apparently preferentially affected.
Effects ofcycloheximide on apoB degradation. Preliminary experiments indicated that 10 jg/ml of cycloheximide inhibited over 95% ofprotein synthesis for at least 4 h without affecting cell viability, as previously reported (26) .
The effects ofcycloheximide on the changes associated with the n-3 fatty acids were explored in two different experimental designs in which the inhibition of protein synthesis was either TIME (min) Figure 7 . FA effects on the total recovery of labeled apoB after pulse-labeling. Data for the total labeled apoB (sum of apoB 100 and apoB48 in the cell and medium) measured at the end of each chase period were taken from Table IV. The y-axis represents the recovery of labeled apoB as the mean percentage of the peak value of [35S]-methionine incorporated into apoB. The x-axis is the duration of the chase period. At 45 min, the percent recovery in the OA group (101±9) was slightly higher than that in the BSA group (91±3, P < 0.05). concurrent with or followed the fatty acid treatment, as described in Methods. At the conclusion of both types of experiments, immunoprecipitation analysis and electrophoresis were performed as above, and quantitative information obtained by cutting out the apoB-related gel bands and assaying the incorporated radioactivity by scintillation counting. As shown in Fig. 8 , left, when cycloheximide was added concurrent with fatty acid treatment (first design), secretion of radiolabeled apoB was still significantly decreased by EPA and DHA relative to OA or BSA. As compared to the results in the OA group, apoB100 and apoB48 were decreased by 38% and 46%, respectively, in the presence of EPA, and 30% and 42%, respectively, in the presence of DHA (P < 0.05, n = 3). In experiments in which cycloheximide was added after treatment with fatty acids had begun (second design), as compared to OA, the reduction in the secetion of newly synthesized apoB in the presence of EPA was even more dramatic ( Fig. 8, right ; as compared to OA, the decreases in apoB100 and apoB48 were 85% and 72%, respectively). It is clear from both experimental designs that active protein synthesis was not required to demonstrate the effects of the n-3 fatty acids. That the decrease observed when cycloheximide was added after fatty acid treatment had begun was greater was a consequence of the reduced steady-state level of apoB in the cells that resulted from the exposure to EPA before cycloheximide was added to the medium. Since EPA was continued in the incubation medium, the intracellular level of apoB continued to fall. In contrast, in the first design, at the time cycloheximide was added the steady-state levels of apoB in the cells were higher, since labeling was done in the absence of the fatty acid treatments. Overall, these results indicated that both the initiation and the maintenance ofthe effects of n-3 fatty acids on the secretion ofnewly synthesized apoB were relatively independent ofprotein synthesis.
Discussion
The central importance of apoB to the ability of the liver to secrete TG-rich lipoproteins has been long appreciated from both experimental studies (for example, 26) and the characterization of patients with abetalipoproteinemia (27) . The impairment ofthis ability by EPA and DHA without limitation of TG synthesis (Fig. 1 ) suggested that the apoB available for lipoprotein production may have been reduced by changes in its synthesis or degradation. We also considered the possibility that impaired secretion of apoB, which resulted in its intracellular accumulation, was an explanation for our results.
After labeling cells with [35S ] methionine to steady-state, it was apparent that rather than accumulating in cells incubated with EPA and DHA, there were reduced levels ofboth apoB48 and apoB 100, as compared to OA (Fig. 2 , Table I ). The initial synthetic rates of apoB in the different treatment groups were comparable (Fig. 3) , consistent with the constitutive levels of apoB mRNA (Table II) . Based on the steady-state and synthetic studies, the most likely explanation for our results was that in the presence ofEPA and DHA, the degradation ofapoB was increased, and a series of pulse-chase experiments was undertaken to test this possibility directly.
After pulse-labeling with [35S] methionine, the recoveries of apoB100 and apoB48 during the chase periods in either compartment (cell lysate, conditioned medium) were considerably decreased when cells were incubated with EPA or DHA (Figs. 4-7; Table IV ). The differences in cellular apoB among treatments could be seen as early as 45 min of chase and increased over the course of the 1 50-min chase period. The effects of n-3 fatty acids on secreted apoB appeared as early as 60 min of chase and persisted through the 90-and 1 50-min periods. This lag between detecting differences in cellular and secreted apoB was expected because of the well-known delay in the appearance of newly synthesized secretory proteins into the medium. By 150 min ofchase, as compared to the results for the OA and BSA groups, in the EPA and DHA groups, only approximately halfas much labeled apoB was recovered in the cells and media (Fig. 7, Table IV) . Thus, the effects of EPA and DHA on the secretion of newly synthesized apoB were quantitatively accounted for by increased intracellular apoB degradation.
The effects of EPA and DHA on apoB degradation did not require active protein synthesis, as demonstrated by the experiments with cycloheximide (Fig. 8) . Besides showing that both the induction and maintenance of the effects were still detectable, in spite of a > 95% reduction in new protein synthesis, these data support the conclusion that n-3 fatty acids exert their effects not on the synthesis but on the intracellular degradation of apoB.
From the pulse-chase and steady-state data we were also able to analyze other aspects of apoB metabolism under the different treatment conditions. As compared to the OA group, in the BSA group the cellular content of steady-state labeled apoB was lower (Table I, Fig. 2 ), but in the pulse-chase experiment, the accumulation of labeled apoB in the medium was greater (Fig. 5 ) and the recovery ofapoB was similar (Table IV, Fig. 7) . Overall, then, the data are consistent with a shorter intracellular half-life of apoB in the BSA group, which was indeed the case (Table III, Fig. 4) , indicating a higher fractional rate of apoB secretion. This would ultimately result in a smaller intracellular pool of apoB in the presence of BSA, just as we found (Table I, Fig. 2) . The difference in the rate ofapoB secretion between the two groups could be due to a primary increase in the BSA group, or, alternatively, a decrease in the OA group reflecting the time required to assemble or secrete relatively TG-rich apoB-containing particles.
In the initial experiment ( Fig. 1 (Fig. 4 , bottom; Table III), in contrast to the BSA group, increased apoB degradation in the n-3 fatty acid groups contributed significantly to this accelerated intracellular decay. While it may be possible that differential effects of EPA and DHA on apoB secretory rates were involved in the shorter intracellular halflife ofapoB 100 vs. apoB48 (Table III) and the reduced average ratio of labeled apoB 100 to apoB48 observed in the media at 150 min of chase (0.24 vs. 0.36 for the OA and BSA groups, as noted in Results), it is more likely that some preference for apoB100 in the stimulated degradative process was responsible: as calculated from the data in Table IV , after 150 min of chase, in the n-3 fatty acid groups the average recovery of apoB100 was less than that of apoB48 (36% vs. 47% of the corresponding average recoveries in the OA and BSA groups).
Our results can be compared to those of recent studies. Sparks and Sparks have reported (16) that there was a stimulation by insulin of the degradation of newly synthesized apoB100 and apoB48 that favored the apoB100 species. It has also been recently reported that in hepatocytes of rats that had consumed diets enriched with n-3 fatty acids, there may have been increased degradation of apoB (28) . This was suggested by the presence of short peptides in the conditioned media reactive with an antibody directed against rat apoB. Lang and Davis (6) have reported that after steady-state labeling of rat primary hepatocytes in the presence of FA-BSA complexes, although there were reductions in the secretion ofnewly synthesized apoB associated with EPA and DHA, there was no significant difference between n-3 fatty acid and OA treatments in the cellular levels of apoB labeled to steady-state. However, the cellular measurements were rather variable and effects on the order of those observed in the present work may have been obscured. Another potential factor contributing to the negative results of Lang and Davis was the longer treatment period they used (18 vs. 4 
h).
In HepG2 cells, Dixon et al. (29) showed that relative to BSA, OA stimulated apoB secretion by 2.5-fold primarily by inhibiting the intracellular degradation of apoB. The HepG2 results are not consistent with the present and previous studies in hepatocytes isolated from ad-lib fed rats (6, 26) in which the addition of OA to cultures of those cells did not result in an increased accumulation of apoB in the conditioned medium. The reasons for this discrepancy are not clear, but may related to differences in the cell types. For example, in the absence of added free fatty acids, true VLDL particles are not produced by HepG2 cells. Also, as compared to primary cells, they have additional energy requirements that may be partially met by using exogenous fatty acids as primarily fuel sources. Perhaps HepG2 cells resemble hepatocytes from fasted rats, which differ dramatically from hepatocytes from ad-lib fed rats by increasing their secretion of apoB in response to oleic acid (30) .
Although Borchardt and Davis (15) reported in 1987 that a large proportion of newly synthesized apoB can be degraded intracellularly in rat hepatocytes, indicating that apoB is subject to a highly active sorting process, this process as well as other aspects of cellular apoB-containing particle metabolism remain incompletely documented or controversial. There are divergent views on such matters as the site of initial lipid transfer (the rough endoplasmic reticulum [31, 32] vs. the smooth endoplasmic reticulum [25, 33] ) and the organelle in which apoB resides the longest (endoplasmic reticulum [15, 34] vs. Golgi apparatus [35, 36] ); however, in recent reports there is good evidence that during translation, apoB is not completely translocated across the endoplasmic reticulum membrane and remains membrane-bound (31,32,37-39). Presumably, this apoB could be targeted to either a lipoprotein assembly/secretion pathway or to degradation.
The n-3 fatty acids could exert their effects by either interfering with lipoprotein assembly and targeting apoB to a degradative pathway, or directly stimulating the degradation of apoB. Potential effects of EPA and DHA would include induced changes in the metabolic pathways of cholesterol, cholesteryl esters, triglycerides, and phospholipids, in that decreases in the synthesis or availability of these key lipoprotein components are factors known to have the potential to reduce apoB-containing particle secretion (for example, see references [40] [41] [42] .
Also to be considered is the possibility that in the presence of EPA and DHA, apoB is not appropriately co-or post-translationally modified. For example, apoB in rat and man is fatty acylated (43, 44) . Acylation can affect both the ability of proteins to cross membranes and the folding ofproteins (45) . N-3 fatty acids might influence the acylation process in a variety of ways that promote apoB degradation or interfere with lipoprotein assembly.
It is clear that more data will be needed to support any potential model for the mechanism by which n-3 fatty acids lead to increased intracellular apoB degradation. In addition, the compartment ofthe cell in which the increased degradation occurs needs to be identified by cell fractionation methods, in case the step(s) affected by EPA and DHA occur outside the ER, for example, during maturation of nascent lipoproteins in the Golgi.
Whatever the nature or location of the mechanism, based on the experiments using cycloheximide, it does not seem to require active protein synthesis. It must also be rapid in onset and quickly reversible, because in pulse-chase experiments in which fatty acids were omitted during the chase periods no significant effects were observed: although n-3 fatty acids were present for 4 h before the pulse of [35S] methionine, ifthey were subsequently withdrawn during the chase period, by the end of 60 min the recovery of apoB was comparable to that in the OA and BSA groups (87.8% for the EPA and DHA groups vs. 88.2% for the OA and BSA groups).
In summary, our results clearly demonstrate that in the rat hepatocyte, the decreased secretion of newly synthesized apoB in the presence ofthe n-3 fatty acids EPA and DHA is a consequence of increased intracellular degradation ofboth apoB100 and apoB48. Thus, apoB degradation is not a constitutive process, but can be regulated by a nutritional factor.
